diarypharma. The head of the Division of Biological Medicines, Biotechnology and Advanced Therapies of the amemps y chair of the Biological Group of theEMA, sun ruiz, was in charge of moderating the biosimilars table organized within the framework of BioSpain 2016 and establishing some outstanding conclusions regarding the way to promote the incorporation of biological medicines. 'There are experiences in Nordic countries in which the prescription of some biosimilars by clinicians has been forced. From a scientific point of view, it could be correct, but I think thatit is better if you introduce them gradually, building trust in the professionals, even in the patients', he pointed.